Minerva Neurosciences reported $-9764000 in Pre-Tax Profit for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Acadia Pharmaceuticals ACAD:US $ -112.57M 69.67M
Adma Biologics ADMA:US $ -18.34M 1.69M
Biocryst Pharmaceuticals BCRX:US $ -73.92M 58.39M
Bristol Myers Squibb BMY:US $ 5386M 595M
Dynavax Technologies DVAX:US $ 32.86M 67.73M
Esperion Therapeutics ESPR:US $ -56731000 8.39M
Halozyme Therapeutics HALO:US $ 81.63M 20.43M
Johnson & Johnson JNJ:US $ 8218M 1879M
Marinus Pharmaceuticals MRNS:US $ -19.36M 8.94M
Merk MRK:US $ 6309M 1525M
Minerva Neurosciences NERV:US $ -9.76M 13.35M
Neurocrine Biosciences NBIX:US $ 21.4M 35.2M
Novartis NOVN:VX SF 3912M 230M
Novavax NVAX:US $ 206.07M 1035.74M
Pfizer PFE:US $ 11328M 4083M
Sanofi SAN:FP € 2965M 804M
Takeda 4502:JP Y -54047M 126240M
Vanda Pharmaceuticals VNDA:US $ -7.56M 16.17M